HCW Biologics Inc.: insider trades · United States · SEC (Form 4)

About HCW Biologics Inc.

HCW Biologics Inc. (Nasdaq: HCWB) is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States and headquartered in Miramar, Florida, United States. Founded in 2018 by Dr. Hing C. Wong, the company is focused on developing next-generation immunotherapies designed to address diseases driven by chronic inflammation and biological aging, often described by management as “inflammaging.” Its overarching thesis is to improve healthspan by intervening in inflammatory pathways linked to cancers, autoimmune disorders, neurodegenerative conditions and other senescence-associated diseases. Operationally, HCW Biologics centers its research and development efforts on proprietary fusion immunotherapeutics built on its TRBC platform, which stands for T-cell Receptor beta Chain constant region. This technology platform is the company’s core differentiator and underpins several classes of product concepts, including multifunctional immune stimulators, second-generation immune checkpoint inhibitors, multispecific targeting fusions and immune-cell engagers. Two of the most visible programs are HCW11-018b, a second-generation tetravalent T-cell engager, and HCW11-040, a pembrolizumab-based tetravalent immune checkpoint inhibitor, both aimed at solid-tumor indications. The company also references commercial-ready proprietary compounds intended for use as reagents in the production of immunotherapeutics, although HCW remains primarily a development-stage organization. From a competitive perspective, HCW Biologics operates in a crowded and capital-intensive biotech landscape dominated by much larger companies. Its investment case is therefore driven by scientific differentiation, platform optionality and the potential to generate high-value assets in difficult therapeutic areas rather than by scale or current revenue generation. For investors, this implies a classic small-cap biotech risk profile: substantial upside if clinical and regulatory milestones are achieved, but meaningful dependence on capital access, data quality and execution. The company’s geographic footprint is overwhelmingly U.S.-centric, with its principal executive office in Miramar, Florida, and its operating strategy anchored in discovery and development rather than a broad commercial sales infrastructure. That makes HCW Biologics more of an innovation platform than a mature pharmaceutical business. Recent company developments have been active. In May 2026, HCW Biologics reported first-quarter 2026 business highlights and financial results and announced further updates for its T-cell engager program, including new data on mechanism of action and validation of Tissue Factor as a target for solid tumors. The company also highlighted its inclusion in the S&P TMI Index in 2026, which can improve visibility among institutional investors, while continuing to manage the financing and listing-related issues that are common for early-stage public biotech companies. Overall, HCWB should be viewed as a speculative NASDAQ-listed biotechnology name with value creation tied primarily to clinical progress and platform validation, not to recurring commercial sales.